Pharmacokinetic evaluation of two pirfenidone formulations in patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by an abnormal activation of lung epithelium and fibroblasts, as well as an excessive accumulation of extracellular matrix. Pirfenidone was introduced as a therapeutic option for IPF and chronic hypersensitive pneum...
Main Authors: | Lina Marcela Barranco-Garduño, Ivette Buendía-Roldan, Juan Jose Rodriguez, Rodrigo González-Ramírez, Ariadna N. Cervantes-Nevárez, Juan Carlos Neri-Salvador, Miriam del Carmen Carrasco-Portugal, Gilberto Castañeda-Hernández, Karen Martinez-Espinosa, Moisés Selman, Francisco Javier Flores-Murrieta |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-10-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844020321228 |
Similar Items
-
Hypersensitivity Pneumonitis: Diagnostic and Therapeutic Challenges
by: Maria Laura Alberti, et al.
Published: (2021-09-01) -
Evaluation of the efficacy of pirfenidone in progressive chronic hypersensitivity pneumonitis
by: Eman Shebl, et al.
Published: (2021-03-01) -
Immunoglobulin free light chains are increased in hypersensitivity pneumonitis and idiopathic pulmonary fibrosis.
by: Tom Groot Kormelink, et al.
Published: (2011-01-01) -
Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis
by: Evans R. Fernández Pérez, et al.
Published: (2021-06-01) -
Hypersensitivity pneumonitis
by: Cormier Yvon, et al.
Published: (2006-07-01)